Search results
Results From The WOW.Com Content Network
Pathophysiology of HIV/AIDS. HIV is commonly transmitted via unprotected sexual activity, blood transfusions, hypodermic needles, and from mother to child. Upon acquisition of the virus, the virus replicates inside and kills T helper cells, which are required for almost all adaptive immune responses. There is an initial period of influenza-like ...
During those visits, providers should repeat testing for HIV, test for other sexually transmitted infections, monitor kidney function, and/or test for pregnancy. [ 18 ] [ 2 ] Individuals must test negative for HIV prior to PrEP initiation because persons infected with HIV taking PrEP medication are at risk for becoming resistant to emtricitabine.
Management of HIV/AIDS. The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [ 1 ] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active ...
Post-exposure prophylaxis. Other names. Post-exposure prevention. [edit on Wikidata] Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring. It should be contrasted with pre-exposure prophylaxis, which is ...
HIV latency. Human Immunodeficiency Virus (HIV) has the capability to enter a latent stage of infection where it exists as a dormant provirus in CD4+ T-cells. Most latently infected cells are resting memory T cells, [ 1] however a small fraction of latently infected cells isolated from HIV patients are naive CD4 T cells. [ 2]
Infectious disease, neurology. HIV-associated neurocognitive disorders (HAND) are neurological disorders associated with HIV infection and AIDS. It is a syndrome of progressive deterioration of memory, cognition, behavior, and motor function in HIV-infected individuals during the late stages of the disease, when immunodeficiency is severe. [ 1 ]
GSK's new HIV drug formula could support longer dosing intervals March 5, 2024 at 9:26 AM (This March 4 story has been corrected to remove a reference to declining revenue from current bestsellers ...
Following infection with HIV, the rate of clinical disease progression varies enormously between individuals. Many factors such as host susceptibility and immune function, [2] [3] [4] health care and co-infections, [5] [6] [7] as well as factors relating to the viral strain [8] [9] may affect the rate of clinical disease progression.